Compare TRDA & CPZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | CPZ |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.3M | 257.4M |
| IPO Year | 2021 | 2017 |
| Metric | TRDA | CPZ |
|---|---|---|
| Price | $4.55 | $12.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 327.2K | 69.0K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,421,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $87.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.11 | $12.31 |
| 52 Week High | $16.45 | $15.80 |
| Indicator | TRDA | CPZ |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 41.49 |
| Support Level | N/A | $12.40 |
| Resistance Level | $7.89 | $13.17 |
| Average True Range (ATR) | 0.43 | 0.16 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 19.33 | 31.84 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Calamos L/S Equity & Dynamic Inc Trust is a trust company that seeks to provide current income and risk-managed capital appreciation, with an investment objective to deliver total return through a combination of capital appreciation and current income. The Fund invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary, and others, and holds securities with a broad range of maturities, with the average term to maturity typically ranging from two to ten years. Managed assets represent the Fund's total assets, including any assets attributable to leverage that may be outstanding, minus total liabilities other than debt representing financial leverage.